Products

CUDC-101

CUDC-101

CUDC-101

CAS No.: 1012054-59-9

Category Products

Cat.NO.:A165599 Purity:98%

Product Details of CUDC-101

CAS No. :	1012054-59-9
Formula :	C₂₄H₂₆N₄O₄
M.W :	434.49
SMILES Code :	O=C(NO)CCCCCCOC1=CC2=C(NC3=CC=CC(C#C)=C3)N=CN=C2C=C1OC
Synonyms :	CUDC-101
MDL No. :	MFCD15528940
InChI Key :	PLIVFNIUGLLCEK-UHFFFAOYSA-N
Pubchem ID :	24756910

Safety of CUDC-101

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Related Pathways of CUDC-101

epigenetics

RTK

JAK-STAT

Isoform Comparison

Biological Activity

Target

HDAC8

HDAC8, IC50:79.8 nM
HDAC10

HDAC10, IC50:26.1 nM
HDAC3

HDAC3, IC50:9.1 nM
HDAC4

HDAC4, IC50:13.2 nM

Clinical Trial:

NCT Number	Conditions	Phases	Recruitment	Completion Date	Locations

NCT00728793	Tumors	PHASE1	COMPLETED	2025-04-10	Karmanos Cancer Institute, Det… More >>roit, Michigan, 48201, United States\|START (South Texas Accelerated Research Therapeutics), San Antonio, Texas, 78229, United States Less <<
NCT01702285	Cancer	PHASE1	TERMINATED	2025-12-12	Karmanos Cancer Institute, Det… More >>roit, Michigan, 48201, United States\|Southern Texas Accelerated Research Therapeutics, San Antonio, Texas, 78229, United States Less <<

Protocol

Bio Calculators

Preparing Stock Solutions

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.30mL

0.46mL

0.23mL

11.51mL

2.30mL

1.15mL

23.02mL

4.60mL

2.30mL

References

[1]Lai CJ, Bao R, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 2010 May 1;70(9):3647-56.

[2]Cai X, Zhai HX, et al. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 2010 Mar 11;53(5):2000-9.

[3]Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 2010 Mar 11;53(5):2000-9.

[4]Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, Keegan M, Pepicelli CV, Qian C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 2010 May 1;70(9):3647-56.

Details

Reviews

There are no reviews yet.

Be the first to review “CUDC-101”

Previous

PTZ-343

Next

2-(4-Methylbenzyl)isoindoline-1,3-dione